Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 809

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 809
---
 the Company in the years ended December 31, 2023, 2022 and 2021 are included in the following table:

| ​                          
 ​                          
 ​                          | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Revenue                 
 Year Ended December 31, 
 2023                    |   |     |   | ​ | ​ | 2022 |   |      |   | ​ | ​ | 2021 |   |     |   | ​ 
 ​ 
 ​ |
|:---------------------------|:--|:--|:------------------------|:--|:----|:--|:--|:--|:-----|:--|:-----|:--|:--|:--|:-----|:--|:----|:--|:--|
| License Agreement Partner: | ​ | ​ | ​                       | ​ | ​   | ​ | ​ | ​ | ​    | ​ | ​    | ​ | ​ | ​ | ​    | ​ | ​   | ​ | ​ |
| CSL Vifor*                 | ​ | ​ | ​                       | ​ | 92% | ​ | ​ | ​ | ​    | ​ | 100% | ​ | ​ | ​ | ​    | ​ | 92% | ​ | ​ |

* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022. For the years ended December 31, 2023, 2022 and 2021, no additional license agreement partners or customers accounted for more than 10% of the Company’s revenue. Concentration of Suppliers The Company relies on three suppliers to manufacture KORSUVA injection active pharmaceutical ingredient, or API, finished drug product, and finished goods. If any of the Company’s suppliers were to limit or terminate production or otherwise fail to meet the quality or delivery requirements to satisfy the supply commitments, the process of locating and qualifying alternate sources would require up to two years, during which time production could be delayed. Such delays could have a material adverse effect on the Company’s business, financial position, and results of operations. Cash and Cash Equivalents Cash and cash equivalents include cash on hand, demand deposits, deposits with banks and highly liquid money market funds with holdings of cash and other investments with original maturities of